Price Target Update on Intrexon Corporation (NYSE:XON)

Intrexon Corporation (NYSE:XON) : 8 Wall Street analysts covering Intrexon Corporation (NYSE:XON) believe that the average level the stock could reach for the short term is $48.13. The maximum price target given is $65 and the minimum target for short term is around $29, hence the standard deviation is calculated at $12.68.

Other Equity analysts have also commented on the company shares. JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON). According to the latest information available, the shares are now rated Market Outperform by the analysts at the agency. The rating by the firm was issued on May 3, 2016.

Intrexon Corporation (NYSE:XON): stock turned positive on Thursday. Though the stock opened at $24.56, the bulls momentum made the stock top out at $25.3 level for the day. The stock recorded a low of $24.44 and closed the trading day at $25.2, in the green by 2.23%. The total traded volume for the day was 1,967,749. The stock had closed at $24.65 in the previous days trading.

The company shares have dropped -49.88% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $69.45 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $26.99 and the 200 Day Moving Average price is recorded at $30.56. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Intrexon Corp, Kirk Randal J, had purchased 124,475 shares in a transaction dated on December 11, 2015. The transaction was executed at $29.84 per share with total amount equaling $3,714,334.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.